On July 14, 2026 Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, reported that updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b clinical trial (NCT06026410) evaluating darlifarnib in combination with cabozantinib in advanced renal cell carcinoma (RCC) will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit (KCRS) in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will highlight long-term follow-up results in heavily pretreated cabozantinib-naïve patients with refractory RCC, providing further evidence of darlifarnib’s potential as a combination agent with VEGFR-targeted therapies, a widely used treatment approach in this patient population. RCC is the most common form of kidney cancer, and clear cell RCC (ccRCC) is the most common histology in RCC, accounting for more than 61,000 new cases in the U.S. each year.1
"Despite meaningful advances in the treatment of renal cell carcinoma, there remains a significant need for combination strategies capable of delivering deeper and more durable responses," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "The updated FIT-001 data will further inform the potential of darlifarnib plus cabozantinib as a precision combination strategy in advanced ccRCC. More broadly, Kura’s KCRS presentation builds on the growing body of clinical evidence supporting darlifarnib’s mechanism of action across VEGF-TKI, KRAS and PI3Ka inhibitor combinations, supporting darlifarnib’s potential to enhance clinical activity of these targeted-therapy backbones."
The KCRS presentation adds to the FIT-001 RCC results presented at ESMO (Free ESMO Whitepaper) 2025 and additional findings in cabozantinib-exposed ccRCC patients presented at 2026 IKCS: Europe.
Kura is currently enrolling patients in the U.S. and E.U. in the randomized Phase 1b dose-optimization portion of FIT-001 in cabozantinib-naïve, refractory, advanced ccRCC. The randomized Phase 1b portion is evaluating darlifarnib plus cabozantinib versus cabozantinib alone and is designed to inform selection of a recommended Phase 3 dose for a registrational study planned for 2028.
The KCRS presentation represents another step in Kura’s broader strategy to establish darlifarnib as a precision combination agent capable of enhancing multiple targeted therapy classes through inhibition of adaptive mTORC1 signaling. The first planned expansion is expected to evaluate darlifarnib in combination with daraxonrasib in previously treated RAS-mutated pancreatic ductal adenocarcinoma.
2026 KCRS Presentation Details
Title: Farnesyl transferase inhibitor (FTI) darlifarnib combined with cabozantinib in renal cell carcinoma (RCC): Updated phase 1a results from FIT-001
Date: July 24, 2026
Time: 3:05 p.m. – 3:45 p.m. ET
Virtual Investor Event
Kura will host a webcast and conference call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET featuring management and Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology and Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About darlifarnib
Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling, a pathway implicated in adaptive signaling across multiple targeted therapy settings. By suppressing adaptive mTORC1 signaling, darlifarnib is designed to counter a key mechanism of resistance to targeted therapies, with the goal of enhancing the depth and durability of response across multiple targeted therapy classes.
(Press release, Kura Oncology, JUL 14, 2026, View Source [SID1234669208])